Resumo:
MO40598_POLARGO
Estudo fase III, aberto, multicêntrico, randomizado, avaliando a segurança e a eficácia de Polatuzumabe Vedotina em combinação com Rituximabe mais Gencitabina mais Oxaliplatina (R-Gemox) versus R-Gemox isoladamente, em pacientes que apresentam linfoma difuso de grandes células B recidivante/refratário
Patrocinador:
Roche
Resumo:
Salvador / BA
Instituição: IDOR Salvador
Informações: 11 94257-9076 (WhatsApp) / 11 2109-8804
E-mail: nucleodecaptacao@idor.org
Cookie | Duração | Descrição |
---|---|---|
cookielawinfo-checkbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
cookielawinfo-checkbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
cookielawinfo-checkbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |